Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug trial registration/disclosure rule in China signals more inspections

This article was originally published in SRA

Executive Summary

China has introduced registration and disclosure requirements for drug clinical studies that, while their ostensible purpose is to enhance transparency, may also be a prelude to increased clinical trial site inspections by the country's regulator1,2.

You may also be interested in...



EMA Starts ‘Rolling Review’ Of AstraZeneca’s COVID-19 Vaccine

The European Medicines Agency says its rolling review tool should speed up the evaluation of AstraZeneca’s COVID-19 vaccine.

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Blueprint Medicines' Ayvakyt for treating unresectable or metastatic gastrointestinal stromal tumors. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization announcement and product type (eg, medicine, vaccine, biologic).

Italy: Pharma May Have To Disclose Confidential Info Under New Pricing Rules

Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel